$Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer$

Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

Bibliographic Details
Main Authors:	Rafael Rosell, Martyna Filipska, Imane Chaib, David Lligé, Fernando Laguia
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-09-01
Series:	Frontiers in Oncology
Subjects:	PD-1 PD-L1 T Cells CRISPR PI3K Akt
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2020.01726/full

Similar Items

IFIT3 accelerates the progression of head and neck squamous cell carcinoma by targeting PD-L1 to activate PI3K/AKT signaling pathway
by: Peng Liu, et al.
Published: (2024-01-01)

Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
by: Mariacarmela Santarpia, et al.
Published: (2020-06-01)

Reversing T Cell Exhaustion by Converting Membrane PD-1 to Its Soluble form in Jurkat Cells; Applying The CRISPR/Cas9 Exon Skipping Strategy
by: Zeinab Yousefi-Najafabadi, et al.
Published: (2023-09-01)

Immune‐independent acquired resistance to PD‐L1 antibody initiated by PD‐L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib
by: Yuan Gao, et al.
Published: (2023-07-01)

A new PD(1+PI) direct power controller for the variable-speed multi-rotor wind power system driven doubly-fed asynchronous generator
by: Habib Benbouhenni, et al.
Published: (2022-11-01)

INPP4B inhibits glioma cell proliferation and immune escape via inhibition of the PI3K/AKT signaling pathway
by: Xiaoming Sun, et al.
Published: (2022-09-01)

Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells
by: Mingshui Chen, et al.
Published: (2019-02-01)

Upregulation of programmed cell death 1 by interferon gamma and its biological functions in human monocytes
by: Kittitach Sri-ngern-ngam, et al.
Published: (2022-12-01)

Sema4D silencing increases the sensitivity of nivolumab to B16-F10 resistant melanoma via inhibiting the PI3K/AKT signaling pathway
by: Zhuo Zhang, et al.
Published: (2023-04-01)

Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells
by: Alexis Rugamba, et al.
Published: (2021-06-01)

Gypenoside induces apoptosis by inhibiting the PI3K/AKT/mTOR pathway and enhances T-cell antitumor immunity by inhibiting PD-L1 in gastric cancer
by: Hongliang Wu, et al.
Published: (2024-02-01)

Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth
by: Tsutomu Nakazawa, et al.
Published: (2020-04-01)

Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab
by: Brooke C. Bloom, et al.
Published: (2019-04-01)

Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
by: Takuma Isshiki, et al.
Published: (2018-10-01)

Use of dual-transfection for programmed death cell protein 1 disruption mediated by CRISPR-Cas9 in human peripheral blood mononuclear cells
by: Seyed Ali Alambeladi, et al.
Published: (2021-01-01)

Effects of IGF-1 on Proliferation, Angiogenesis, Tumor Stem Cell Populations and Activation of AKT and Hedgehog Pathways in Oral Squamous Cell Carcinoma
by: Jéssica Mariane Ferreira Mendes, et al.
Published: (2020-09-01)

Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck
by: Sebastian Zahnreich, et al.
Published: (2021-02-01)

Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
by: Samantha N. Reiss, et al.
Published: (2017-12-01)

Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer
by: Christophe Glorieux, et al.
Published: (2022-09-01)

PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
by: Min Luo, et al.
Published: (2021-10-01)

Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors
by: Yoichi Shida, et al.
Published: (2021-09-01)

Programmed Cell Death-1 and Its Ligands as Targets for Therapy of Multiple Myeloma Patients
by: Karczmarczyk A, et al.
Published: (2022-03-01)

Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma
by: Manal Mohamed Saber
Published: (2022-02-01)

PD-1-Mediated PI3K/Akt/mTOR, Caspase 9/Caspase 3 and ERK Pathways Are Involved in Regulating the Apoptosis and Proliferation of CD4+ and CD8+ T Cells During BVDV Infection in vitro
by: Yu Liu, et al.
Published: (2020-03-01)

The clinical association of programmed death-1/PD-L1 axis, myeloid derived suppressor cells subsets and regulatory T cells in peripheral blood of stable COPD patients
by: Mingqiang Zhang, et al.
Published: (2024-03-01)

Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy
by: Chunmeng Wang, et al.
Published: (2021-07-01)

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
by: Kazushige Yoshida, et al.
Published: (2020-01-01)

Inhibition of PI3K Isoform p110γ Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity
by: Kelvin Anderson, et al.
Published: (2021-02-01)

Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer
by: Xiaoyu ZHI, et al.
Published: (2019-12-01)

Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non‐small cell lung cancer: Chinese multicenter report and literature review
by: Tao Zhang, et al.
Published: (2020-10-01)

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
by: Yi Que, et al.
Published: (2021-07-01)

Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy—A Review
by: Katarzyna Król, et al.
Published: (2023-03-01)

Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer
by: Katia Khoury, et al.
Published: (2020-08-01)

A Case of Systemic Severe Bullous Pemphigoid Caused by Long-Term Sintilimab Treatment for Renal Cell Carcinoma
by: He J, et al.
Published: (2022-08-01)

Assays for predicting and monitoring responses to lung cancer immunotherapy
by: Cristina Teixidó, et al.
Published: (2015-06-01)

Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer
by: Guangsheng Zhu, et al.
Published: (2021-03-01)

Intrinsic and Extrinsic Transcriptional Profiles That Affect the Clinical Response to PD-1 Inhibitors in Patients with Non–Small Cell Lung Cancer
by: Hye Eun Byeon, et al.
Published: (2022-12-01)

NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer
by: Tung-Yung Huang, et al.
Published: (2020-08-01)

Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
by: Ching-Yao Yang, et al.
Published: (2020-06-01)

YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity
by: Wing Lam, et al.
Published: (2023-01-01)